I have long championed efforts to improve prescription drug access and affordability for all Americans.

We need to identify avenues for lowering out-of-pocket costs, increasing competition, and promoting access to lifesaving innovation--and we need to do so in a fiscally responsible manner.

I have long championed efforts to improve prescription drug access and affordability for Americans, and I welcome the opportunity to engage in this vitally important bipartisan hearing.

Today, I am introducing legislation called the Lower Drug Costs for Families Act, and what it will do is penalize pharmaceutical companies for increasing the price of their drugs faster than the rate of inflation.

In many ways, Medicare Part D reflects an unprecedented success story, coming in massively under budget, with low and stable monthly premiums--and with a generic drug dispensing rate of roughly 90 percent.

Today, I am introducing legislation called the Lower Drug Costs for Families Act, and what it will do is penalize pharmaceutical companies for increasing the price of their drugs faster than the rate of inflation.

I have long championed efforts to improve prescription drug access and affordability for all Americans.

When we talk about the need for greater transparency in the drug supply chain, that term can and should mean a few different things.

NACDS appreciates the Committee's work to explore PBMs' lack of transparency and standardized performance measures.

We have got to figure out how to strengthen Medicare.

We have to change that.

Congress took a critical step toward addressing these challenges nearly 20 years ago, when we voted to enact Medicare's prescription drug benefit or Part D.

That said, much has changed in the past 2 decades, and we have an obligation both to build on the aspects of Part D that work well and to address access and affordability gaps where we find them.

Some of the most lifesaving medications remain out of reach for far too many working families and seniors.

Obviously, transparency is key.

We need to identify avenues for lowering out-of-pocket costs, increasing competition, and promoting access to lifesaving innovation--and we need to do so in a fiscally responsible manner.

I pay tribute to Jeff Wrase, the U.S. Senate Finance Committee's deputy staff director and chief economist, who recently left the committee after more than 11 years of service. For more than 20 years, Jeff served in what many consider to…

The Fed should focus on its mission and not the climate arena. This is a waste of time, attention, and manpower.

The law and the regulations are crystal clear. The Federal Reserve can take any supervisory or enforcement action it deems necessary to address unsafe and unsound practices.

Given SVB's social and climate agenda, one must ask if SVB's investments in climate caused the regulators to be a bit more permissive of its risks.

Respectfully, an American trade policy cannot rest on massive spending on subsidies. That approach borrows more from China's traditions than ours.

Respectfully, however, an American trade policy cannot rest on massive spending on subsidies.

American trade policy unleashes our people's talent and productivity by removing foreign barriers through tough negotiations and enforcement.

the administration should accordingly partner with Congress and the American people, not try to cut us out, because under the Constitution it cannot.

American trade policy unleashes our people's talent and productivity by removing foreign barriers through tough negotiations and enforcement.